PharmacyCodes



Nitric oxide 10% by volume or more en es it fr

Nitric oxide 10% by volume or more Brand names, Nitric oxide 10% by volume or more Analogs

Nitric oxide 10% by volume or more Brand Names Mixture

  • Aldoril 15 Tab (Hydrochlorothiazide + Methyldopa)
  • Aldoril 25 Tab (Hydrochlorothiazide + Methyldopa)
  • Apo Methazide 15 (Hydrochlorothiazide + Methyldopa)
  • Apo Methazide 25 (Hydrochlorothiazide + Methyldopa)
  • Novo-Doparil 15 Tab (Hydrochlorothiazide + Methyldopa)
  • Novo-Doparil 25 Tab (Hydrochlorothiazide + Methyldopa)
  • Pms-Dopazide 15 Tab (Hydrochlorothiazide + Methyldopa)
  • Pms-Dopazide-25 Tab (Hydrochlorothiazide + Methyldopa)
  • Supres 150 Tab (Chlorothiazide + Methyldopa)
  • Supres 250 Tab (Chlorothiazide + Methyldopa)

Nitric oxide 10% by volume or more Chemical_Formula

NO

Nitric oxide 10% by volume or more RX_link

http://www.rxlist.com/cgi/generic/inomax.htm

Nitric oxide 10% by volume or more fda sheet

Nitric_oxide_10%_by_volume_or_more FDA

Nitric oxide 10% by volume or more msds (material safety sheet)

Nitric_oxide_10%_by_volume_or_more MSDS

Nitric oxide 10% by volume or more Synthesis Reference

No information avaliable

Nitric oxide 10% by volume or more Molecular Weight

30.0061 g/mol

Nitric oxide 10% by volume or more Melting Point

-163.6 oC

Nitric oxide 10% by volume or more H2O Solubility

9.49E+004 mg/L

Nitric oxide 10% by volume or more State

Liquid

Nitric oxide 10% by volume or more LogP

0.10

Nitric oxide 10% by volume or more Dosage Forms

Cream; Drops; Gas; Liquid; Lotion; Ointment; Powder; Tablet

Nitric oxide 10% by volume or more Indication

For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure

Nitric oxide 10% by volume or more Pharmacology

Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, Nitric oxide improves oxygenation (as indicated by significant increases in PaO2). Nitric oxide appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better entilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

Nitric oxide 10% by volume or more Absorption

Nitric oxide is absorbed systemically after inhalation.

Nitric oxide 10% by volume or more side effects and Toxicity

No information avaliable

Nitric oxide 10% by volume or more Patient Information

No information avaliable

Nitric oxide 10% by volume or more Organisms Affected

Humans and other mammals